22nd Century PE Ratio 2011-2023 | XXII
Current and historical p/e ratio for 22nd Century (XXII) from 2011 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. 22nd Century PE ratio as of April 26, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| 22nd Century PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-04-26 |
1.73 |
|
0.00 |
| 2023-12-31 |
2.98 |
$-100.47 |
0.00 |
| 2023-09-30 |
15.64 |
$-129.26 |
0.00 |
| 2023-06-30 |
91.85 |
$-84.77 |
0.00 |
| 2023-03-31 |
184.56 |
$-76.76 |
0.00 |
| 2022-12-31 |
220.92 |
$-69.57 |
0.00 |
| 2022-09-30 |
222.55 |
$-62.37 |
0.00 |
| 2022-06-30 |
511.20 |
$-62.37 |
0.00 |
| 2022-03-31 |
556.80 |
$-55.17 |
0.00 |
| 2021-12-31 |
741.60 |
$-50.37 |
0.00 |
| 2021-09-30 |
710.40 |
$-40.78 |
0.00 |
| 2021-06-30 |
1111.20 |
$-33.58 |
0.00 |
| 2021-03-31 |
789.60 |
$-35.98 |
0.00 |
| 2020-12-31 |
528.00 |
$-35.98 |
0.00 |
| 2020-09-30 |
153.79 |
$-35.98 |
0.00 |
| 2020-06-30 |
183.46 |
$-47.98 |
0.00 |
| 2020-03-31 |
180.00 |
$-52.77 |
0.00 |
| 2019-12-31 |
264.00 |
$-50.37 |
0.00 |
| 2019-09-30 |
542.40 |
$-55.17 |
0.00 |
| 2019-06-30 |
501.60 |
$-26.39 |
0.00 |
| 2019-03-31 |
410.40 |
$-23.99 |
0.00 |
| 2018-12-31 |
597.60 |
$-16.79 |
0.00 |
| 2018-09-30 |
674.40 |
0 |
0.00 |
| 2018-06-30 |
590.40 |
$-16.79 |
0.00 |
| 2018-03-31 |
564.00 |
$-14.39 |
0.00 |
| 2017-12-31 |
672.00 |
$-23.99 |
0.00 |
| 2017-09-30 |
664.80 |
$-31.18 |
0.00 |
| 2017-06-30 |
420.00 |
$-31.18 |
0.00 |
| 2017-03-31 |
283.20 |
$-31.18 |
0.00 |
| 2016-12-31 |
261.60 |
$-33.58 |
0.00 |
| 2016-09-30 |
348.00 |
$-35.98 |
0.00 |
| 2016-06-30 |
194.90 |
$-38.38 |
0.00 |
| 2016-03-31 |
187.92 |
$-33.58 |
0.00 |
| 2015-12-31 |
336.00 |
$-38.38 |
0.00 |
| 2015-09-30 |
201.60 |
$-50.37 |
0.00 |
| 2015-06-30 |
225.60 |
$-52.77 |
0.00 |
| 2015-03-31 |
206.40 |
$-55.17 |
0.00 |
| 2014-12-31 |
396.00 |
$-62.37 |
0.00 |
| 2014-09-30 |
604.80 |
$-79.16 |
0.00 |
| 2014-06-30 |
736.80 |
$-143.93 |
0.00 |
| 2014-03-31 |
780.00 |
$-139.13 |
0.00 |
| 2013-12-31 |
513.60 |
$-117.54 |
0.00 |
| 2013-09-30 |
309.60 |
$-79.16 |
0.00 |
| 2013-06-30 |
170.40 |
$-2.40 |
0.00 |
| 2013-03-31 |
211.20 |
0 |
0.00 |
| 2012-12-31 |
180.00 |
$-19.19 |
0.00 |
| 2012-09-30 |
67.20 |
$-19.19 |
0.00 |
| 2012-06-30 |
84.00 |
$-23.99 |
0.00 |
| 2012-03-31 |
148.80 |
$-33.58 |
0.00 |
| 2011-12-31 |
100.80 |
$-14.39 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Consumer Staples |
Tobacco Products |
$0.006B |
$0.032B |
|
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
|
